It can overcome resistance to endocrine therapy or CDK4/6i, primarily by inducing cellular senescence to suppress tumor proliferation. For instance, resistance can be reversed through RBL2 dephosphorylation and C-MYC–driven senescence, effectively eliminating CDK4/6-resistant clones. Here, RBL2 is linked to neoplasm.